IRIDEX CORP
About IRIDEX CORP
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $52.7M
- Net income
- -$4.4M
- Total assets
- $29.2M
- Market cap
- $19.0M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Balance sheet
- Total assets
- $29.2M
- Current assets
- $25.3M
- Total liabilities
- $24.2M
- Current liabilities
- $13.2M
- Shareholders’ equity
- $4.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $19.0M
- Shares outstanding
- 17.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 16, 1996
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $4.4M in FY2026.
- Revenue grew 34% from FY2020 to FY2024.
- Trading 29% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review IRIDEX CORP.
Write a review
News about IRIDEX CORP
News & sentiment via Polygon.io
